Advances in Recurrent/Metastatic Nasopharyngeal Carcinoma: Immunotherapy and Biomarkers

To participate in this activity, please:

Log in Sign Up

Greater understanding of the tumor microenvironment of nasopharyngeal carcinoma (NPC) has led to the introduction of immunotherapy into the NPC treatment landscape. Incorporating immunotherapy has changed the current standard of care in the treatment of recurrent and metastatic NPC. Robert Ferris, MD, explores clinical trial data leading to approval of PD-1 inhibitors both as monotherapy and in combination with chemotherapy. He also delves into the significance of biomarkers that may influence prognosis and management of patients with NPC, as well as managing toxicity related to PD-1 inhibitors.

Course Credit:

0.50 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2024-10-07
Closes: 2025-10-07

Target Audience:

This activity is intended for medical oncologists, head and neck surgeons, radiation oncologists, physician associates, nurse practitioners, nurses, and pharmacists involved in the care of patients with metastatic nasopharyngeal carcinoma (NPC).

This activity is supported by a grant from Coherus Biosciences.

Accreditation Information

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Rachel Feaster, PharmD, BCOP (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Robert Ferris, MD, PhD

    Associate Senior Vice Chancellor for Cancer Research, Health Sciences
    Hillman Professor of Oncology
    Professor of Otolaryngology, of Immunology, and of Radiation Oncology, School of Medicine
    Director, UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania

Learning Objectives

  • Design evidence-based treatment plans for patients with NPC who are appropriate candidates for immunotherapy.
  • Describe the safety and efficacy of immunotherapy for patients with NPC.
  • Employ appropriate biomarker testing to guide prognosis and management of patients with NPC.
  • Develop appropriate collaborative strategies among the multidisciplinary and interprofessional care team to prevent, identify, and mitigate toxicities related to immunotherapy for the treatment of patients with NPC.

Faculty Disclosures

Robert Ferris, MD, PhD

Advisory Board: Adaptimmune,  Bristol-Myers Squibb, Coherus BioSciences, Inc., CureVac, Eisai Europe Limited,     Genmab, Hookipa Biotech GmbH, Instil Bio, Inc, Lifescience Dynamics Limited, MacroGenics, Inc., MeiraGTx, LLC, Merck, Merus NV, Numab Therapeutics AG, OncoCyte Corporation, Pfizer, Rakuten Medical, Inc, Regeneron, Seagen, Inc, SIRPant Immunotherapeutics, Inc, Vir Biotechnology, Inc

Board of Directors: CytoAgents

Consultant: Adagene Incorporated, Aduro Biotech, Inc., Bicara Therapeutics, Inc, Brooklyn ImmunoTherapeutics LLC, Catenion, EMD Serono, Everest Clinical Research Corporation, F. Hoffmann-La Roche Ltd, Federation Bio, Inc, Genocea Biosciences, Inc, Kowa Research Institute, Inc., Mirati Therapeutics, Inc, Nanobiotix, Novartis Pharmaceutical Corporation, Novasenta, PPD Development, L.P., Sanofi, Zymeworks, Inc.

Data Safety Monitoring Board: Mirror Biologics, Inc.

Research Support: Bristol-Myers Squibb, AstraZeneca/MedImmune, Novasenta, Tesaro